logo
logo

Swanbio Therapeutics Announces $56 Million Series B Financing To Advance Novel Gene Therapies For Neurological Conditions

May 18, 2022•over 3 years ago

Amount Raised

$56 Million

Round Type

series b

Philadelphia

Description

SwanBio Therapeutics, a gene therapy company advancing adeno-associated virus (AAV)-based therapies for the treatment of devastating, inherited neurological conditions, today announced the completion of a $56 million Series B financing round, led by founding investors Syncona Limited and Mass General Brigham Ventures. The new funding brings SwanBio’s total financing raised to date to $133 million.

Company Information

Company

Swan Bio Therapeutics

Location

Philadelphia, Pennsylvania, United States

About

SwanBio Therapeutics is a gene therapy company that aims to bring life-changing treatments to people with devastating, inherited neurological conditions. SwanBio is advancing a pipeline of gene therapies, designed to be delivered intrathecally, that can address targets within both the central and peripheral nervous systems. This approach has the potential to be applied broadly across three disease classifications – spastic paraplegias, monogenic neuropathies, and polygenic neuropathies. SwanBio’s lead program is being advanced toward clinical development for the treatment of adrenomyeloneuropathy (AMN). For more information, visit SwanBioTx.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech